Evaxion biotech announces gonorrhea as second bacterial product target

Copenhagen, denmark, june 30, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, today announced that the company has identified gonorrhea as its second bacterial target for treatment with the company's evx-b2 vaccine product candidate.

EVAX Ratings Summary

EVAX Quant Ranking